Ttracting chemokine-1 (CXCL13) is expressed in germinal center of ectopic lymphoid follicles within the synovium of chronic arthritis sufferers. J Immunol 2001, 166:65055. 7. Manzo A, Vitolo B, Humby F, Caporali R, Jarrossay D, Dell’Accio F, Ciardelli L, Uguccioni M, Montecucco C, Pitzalis C: Mature antigen-experienced T helper cells synthesize and secrete the B cell chemoattractant CXCL13 within the inflammatory atmosphere of your μ Opioid Receptor/MOR Inhibitor web rheumatoid joint. Arthritis Rheum 2008, 58:3377387. eight. Kobayashi S, Murata K, Shibuya H, Morita M, Ishikawa M, Furu M, Ito H, Ito J, Matsuda S, Watanabe T, Yoshitomi H: A distinct human CD4+ T cell subset that secretes CXCL13 in rheumatoid synovium. Arthritis Rheum 2013, 65:3063072. 9. Chan TD, Gatto D, Wood K, Camidge T, Basten A, Brink R: Antigen affinity controls rapid T-dependent antibody production by driving the expansion instead of the differentiation or extrafollicular migration of early plasmablasts. J Immunol 2009, 183:3139149. 10. SSTR4 Activator Storage & Stability Wengner AM, H ken UE, Petrow PK, Hartmann S, Schurigt U, Br er R, Lipp M: CXCR5- and CCR7-dependent lymphoid neogenesis within a murine model of chronic antigen-induced arthritis. Arthritis Rheum 2007, 56:3271283. 11. Rosengren S, Wei N, Kalunian KC, Kavanaugh A, Boyle DL: CXCL13: a novel biomarker of B-cell return following rituximab remedy and synovitis in patients with rheumatoid arthritis. Rheumatology 2011, 50:60310.Greisen et al. Arthritis Study Therapy 2014, 16:434 http://arthritis-research/content/16/5/Page 9 of12. Jones JD, Hamilton BJ, Challener GJ, de Brum-Fernandes AJ, Cossette P, Liang P, Masetto A, M ard HA, Carrier N, Boyle DL, Rosengren S, Boire G, Rigby WF: Serum C-X-C motif chemokine 13 is elevated in early and established rheumatoid arthritis and correlates with rheumatoid factor levels. Arthritis Res Ther 2014, 16:R103. 13. Horslev-Petersen K, Hetland ML, Junker P, Podenphant J, Ellingsen T, Ahlquist P, Lindegaard H, Linauskas A, Schlemmer A, Dam MY, Hansen I, Horn HC, Ammitzboll CG, Jorgensen A, Krintel SB, Raun J, Johansen JS, Ostergaard M, Stengaard-Pedersen K, OPERA study-group, Slot O, Nielsen LK, Skjodt H, Majgaard O, Lorenzen T, Kowalski M, Johansen IL, Pedersen PM, Manilo N, Bliddal H: Adalimumab added to a treat-to-target approach with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis enhanced remission prices, function and excellent of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial. Ann Rheum Dis 2013, 73:65461. 14. Kragstrup TW, Vorup-Jensen T, Deleuran B, Hvid M: A simple set of validation steps identifies and removes false results inside a sandwich enzyme-linked immunosorbent assay brought on by anti-animal IgG antibodies in plasma from arthritis individuals. SpringerPlus 2013, two:263. 15. Bugatti S, Manzo A, Benaglio F, Klersy C, Vitolo B, Todoerti M, Sakellariou G, Montecucco C, Caporali R: Serum levels of CXCL13 are connected with ultrasonographic synovitis and predict power Doppler persistence in early rheumatoid arthritis treated with non-biological disease-modifying anti-rheumatic drugs. Arthritis Res Ther 2012, 14:R34. 16. Meeuwisse CM, van der Linden MP, Rullmann TA, Allaart CF, Nelissen R, Huizinga TW, Garritsen A, Toes RE, van Schaik R, van der Helm-van Mil AH: Identification of CXCL13 as a marker for rheumatoid arthritis outcome utilizing an in silico model in the rheumatic joint. Arthritis Rheum 2011, 63:1265273. 17. Rioja I, Hughes FJ, Sharp CH, Wa.
